Back to Journals » International Journal of Nanomedicine » Volume 15

A Radio-Nano-Platform for T1/T2 Dual-Mode PET-MR Imaging

Authors Gholami YH, Yuan H, Wilks MQ, Maschmeyer R, Normandin MD, Josephson L, El Fakhri G, Kuncic Z

Received 11 December 2019

Accepted for publication 9 February 2020

Published 24 February 2020 Volume 2020:15 Pages 1253—1266


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Phong A Tran

Video abstract of 'A radio-nano-platform for PET-MRI' [ID 241971]

Views: 215

Yaser Hadi Gholami, 1–3 Hushan Yuan, 4 Moses Q Wilks, 4 Richard Maschmeyer, 1 Marc D Normandin, 4 Lee Josephson, 4 Georges El Fakhri, 4 Zdenka Kuncic 1, 2, 5 

1Faculty of Science, School of Physics, The University of Sydney, Sydney, NSW, Australia; 2Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia; 3Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, NSW, Australia; 4Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 5The University of Sydney Nano Institute, Sydney, NSW, Australia

Correspondence: Zdenka Kuncic; Yaser Hadi Gholami
School of Physics A28, The University of Sydney, Sydney, NSW 2006, Australia
Tel +61 2 9351 3162
Fax +61 2 9351 7726

Purpose: This study aimed to develop a chelate-free radiolabeled nanoparticle platform for simultaneous positron emission tomography (PET) and magnetic resonance (MR) imaging that provides contrast-enhanced diagnostic imaging and significant image quality gain by integrating the high spatial resolution of MR with the high sensitivity of PET.
Methods: A commercially available super-paramagnetic iron oxide nanoparticle (SPION) (Feraheme®, FH) was labeled with the [ 89Zr]Zr using a novel chelate-free radiolabeling technique, heat-induced radiolabeling (HIR). Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and radio-thin layer chromatography (radio-TLC). Characterization of the non-radioactive isotope 90Zr-labeled FH was performed by transmission electron microscopy (TEM). Simultaneous PET-MR phantom imaging was performed with different 89Zr-FH concentrations. The MR quantitative image analysis determined the contrast-enhancing properties of FH. The signal-to-noise ratio (SNR) and full-width half-maximum (FWHM) of the line spread function (LSF) were calculated before and after co-registering the PET and MR image data.
Results: High RCY (92%) and RCP (98%) of the [ 89Zr]Zr-FH product was achieved. TEM analysis confirmed the 90Zr atoms adsorption onto the SPION surface (≈ 10% average radial increase). Simultaneous PET-MR scans confirmed the capability of the [ 89Zr]Zr-FH nano-platform for this multi-modal imaging technique. Relative contrast image analysis showed that [ 89Zr]Zr-FH can act as a dual-mode T1/T2 contrast agent. For co-registered PET-MR images, higher spatial resolution (FWHM enhancement ≈ 3) and SNR (enhancement ≈ 8) was achieved at a clinical dose of radio-isotope and Fe.
Conclusion: Our results demonstrate FH is a highly suitable SPION-based platform for chelate-free labeling of PET tracers for hybrid PET-MR. The high RCY and RCP confirmed the robustness of the chelate-free HIR technique. An overall image quality gain was achieved compared to PET- or MR-alone imaging with a relatively low dosage of [ 89Zr]Zr-FH. Additionally, FH is suitable as a dual-mode T1/T2 MR image contrast agent.

Keywords: SPIONs, HIR, radiolabeling, MRI, PET, multimodal imaging

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]